Cancer Profiling Market to Reach US$ 950 Mn in 2019, Breast Cancer Profiling Preeminent, Finds Fact.MR

Monday, December 10, 2018 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

ROCKVILLE, Maryland, December 10, 2018 /PRNewswire/ --

Cancer profiling market revenues surpassed US$

900 million in 2018, according to Fact.MR's latest study. Growing at a subdued 4% y-o-y, the study foresees absolute opportunity of over US$ 36 million in 2019. Steadily rising opportunities in cancer profiling market
can be attributed to,

  • Increasing disease burden of cancer worldwide
  • Significant economic burden associated with cancer diagnosis and treatment
  • Growing R&D investments to develop effective cancer diagnostics
  • Increasing importance of precision medicine adoption and reliance of cancer profiling

     (Logo: https://mma.prnewswire.com/media/713666/FactMR_Logo.jpg )

According to the study, cancer profiling market revenues continue to remain consolidated in North America. Of the estimated new cases, breast cancer accounts for over 15% and colorectal cancer for about 8% new cases. As breast and colorectal cancers are few of the leading causes of death in North America, collectively they register nearly 70% of total regional cancer profiling revenues.

Request For Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=358

The study estimates that Europe represents the second most significant demand for cancer profiling and accounts for over four fifth of the global revenues. Rising incidences of cancer, EU's proactive efforts to promote cancer screening and use of best practices to improve the quality are responsible for the significant investments in cancer profiling space in Europe.

Fact.MR finds that APEJ will register significant utilization of cancer profiling in coming years on the back of rising awareness and adoption of improved tools for cancer identification.

Breast Cancer Accounts for Nearly Half the Cancer Profiling Revenues 

According to the study, breast cancer is expected to take maximum advantage of cancer profiling as compared to other cancer types. After lung cancer, breast cancer is the second most leading cause of new cancer cases.

Globally, national governments are actively engaged in generating awareness regarding the prevention and diagnosis of breast cancer. As cancer profiling applications remain higher in breast cancer diagnosis, a significant fall in breast cancer mortality shows promising diagnosis and improved treatment.

Colorectal cancer is also categorized among one of the leading causes of new cancer cases and cancer deaths. The study finds that followed by breast cancer, a significant utilization of cancer profiling can be observed in colorectal cancer.

Browse Full Report on Cancer Profiling Market with TOC- https://www.factmr.com/report/358/cancer-profiling-market

FISH and IHC Remain Highly Valued Cancer Profiling Techniques 

Cancer profiling constitutes utilization of multiple technologies, of which immunohistochemistry (IHC) and Fluorescent In Situ Hybridization (FISH) are the most reliable technologies preferred by oncologists. Fact.MR reveals that FISH systems register leading revenues in the cancer profiling market, followed by IHC. FISH is the most commonly used technique for cancer profiling among researchers and for cancer diagnosis. Lower cost and higher sensitivity of IHC can be attributed to its significant adoption in cancer profiling.

Fact.MR study estimates that hospitals account for a significant share of the cancer profiling market followed by diagnostic centers. Increasing establishments of multi-speciality hospitals with in-house diagnostic centers are driving the growth of cancer profiling market in hospitals. A considerable utilization of cancer profiling is also found in research laboratories and cancer research institutes.

The cancer profiling marketplace is marked by hefty investments oriented at robust biomarker development to expand cancer profiling capabilities. Lengthy clinical trials present another milestone wherein tedious authorization process of FDA engages significant investments of stakeholders.

The Fact.MR report tracks the cancer profiling market for the period 2018-2028. According to the report, the cancer profiling market is projected to grow at 4.7% CAGR through 2028.

To Buy Cancer Profiling Market Report, Check- https://www.factmr.com/checkout/358/S

About Fact.MR 

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us: Rohit Bhisey Fact.MR 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Email: sales@factmr.com Web: https://www.factmr.com/ Blog: https://factmrblog.com/ Read Industry News at - https://www.industrynewsanalysis.com/  

SOURCE Fact.MR



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store